Boston-based life sciences investor with $2.5B raised since 2004, backing 150+ companies across oncology, immunology, rare diseases, and precision medicine. $650M Fund VII closed oversubscribed in 2022.
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.